Clinical Tool Demonstrates Effectiveness in Assessing COPD, Asthma and Type 2 Diabetes

April 4, 2023 Read in 2 minutes Source/Disclosure Disclosure: Claessens and colleagues do not report relevant financial disclosures. Add topic to email alert Get an email when new articles are posted Enter your email address to receive an email when new articles are posted . " data-actionsubscribe> subscribe Your request could not be processed. Please try again later.If this issue persists, please contact us customerservice@slackinc.com. back to helio Important points: A chronic disease burden assessment tool was developed to facilitate shared decision-making. This tool was effective in distinguishing groups of patients with various chronic diseases. Recent research in Annals of Family Medicine We confirmed the validity and reliability of clinical tools to assess the burden of COPD, type 2 diabetes and asthma. “Effective disease management is essential to the care of people with chronic diseases.” Danny KraesensePhD, Written by doctors from the Department of Family Medicine, Maastricht University in the Netherlands. “A key component of disease management is self-management, which begins with insight into what the patient has experienced with the burden of disease.” The chronic disease burden assessment tool has demonstrated efficacy and reliability in assessing type 2 diabetes, COPD and asthma in patients. Image: Adobe Stock. Researchers found that most questionnaires Unable to ascertain the extent of the burden Because they focus only on quality of life. The Chronic Disease Burden Assessment (ABCC) tool has emerged as a viable resource to support clinical decision-making, capturing the full spectrum of disease burden and comparing generic and disease-specific questionnaires. questionnaire combines both factors. "However, assessing the psychometric properties of the ABCC scale is a necessary element before bringing the ABCC tool into clinical practice," they wrote. Claessens et al. therefore conducted a cross-sectional questionnaire study comparing the ABCC scale with audits of the St. George Respiratory Questionnaire (SGRQ), the Standardized Asthma Quality of Life Questionnaire (AQLQ-S), and the Diabetes Dependent Quality of Life Questionnaire (ADDQoL19). It was conducted. Determine its validity and reliability. The study cohort consisted of 187 Dutch patients. Of those, he had 65 with her COPD, 62 with asthma, and 60 with her type 2 diabetes. Researchers found that the ABCC tool exceeded the efficacy threshold in 75% of comparisons with the SGRQ, 100% of comparisons with the AQLQ-S questionnaire, and 75% of comparisons with the ADDQoL19. Claessens and colleagues highlighted several findings that further support the efficacy of the tool in chronically ill patients. COPD, distinguishing groups of asthma patients and type 2 diabetes; Shows the consistency of the total score with multiple-item domains.and COPD, asthma and type 2 diabetes had intraclass correlation coefficient scores of 0.95, 0.93 and 0.95, respectively, indicating optimal test-retest reliability. They added that the ABCC tool primarily utilizes single-item domains, as opposed to the multiple-item domains that other surveys have. Going forward, "further studies are needed to test the efficacy of the ABCC tool and to evaluate the user experience when using the tool in clinical settings," the researchers concluded. Add topic to email alert Get an email when new articles are posted Enter your email address to receive an email when new articles are posted . " data-actionsubscribe> subscribe Your request could not be processed. Please try again later.If this issue persists, please contact us customerservice@slackinc.com. back to helio Sources 1/ https://Google.com/ 2/ https://www.healio.com/news/primary-care/20230404/clinical-tool-demonstrates-validity-in-assessments-for-copd-asthma-type-2-diabetes The mention sources can contact us to remove/changing this article